# Omeros Corporation (OMER) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $18.95, market value $1.4 billion.

## Valuation
- **P/E (trailing): 11.5×** (5-yr avg 2.5×). Omeros Corporation trades at 11.5× trailing earnings, well above its own five-year average of 2.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 16.6×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.17**. A PEG of 0.17 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 18.6×**. Each dollar of revenue is priced at 18.6×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -5.0%** (5-yr avg -17.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 8.7%**. The inverse of the P/E: 8.7% of the price is earned each year.

## Profitability
- **Operating margin: -212.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Return on equity: 2.8%**. 2.8% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 321.8%**. Return on all capital, debt included, is 321.8%: comfortably above what that capital costs.
- **Return on assets: -42.4%**. Each dollar of assets produces -42.4% of profit.

## Growth
- **EPS growth (1 yr): 98.1%**. Earnings per share rose 98.1%.

## Financial health
- **Net debt / EBITDA: net cash**. Omeros Corporation holds more cash than debt.
- **Interest coverage: -5.9×**. Operating profit covers interest only -5.9×: fragile.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Omeros Corporation does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 353.3%** (YTD 10.3%, 3-mo 93.6%). The shares are up 353.3% over twelve months including dividends.
- **From 52-week high: -3.6%** (381.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 70**. An RSI of 70 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.62** (volatility 190%). Beta of 1.62 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OMER · Page: https://foliofundamentals.com/stocks/omer

Not investment advice.